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a  b  s  t  r  a  c  t
Background:  Cardiovascular  disease  is  the  most  frequent  cause  of mortality  for kidney  transplant  recip-
ients.  Open  heart  surgery  has  particularly  high  mortality  and morbidity.  As  an  alternative  to  traditional
aortic  valve  replacement  (AVR) for patients  with  high-grade  aortic  stenosis,  transcatheter  aortic  valve
implantation  (TAVI)  was  developed  as  an  innovative  therapy  for  patients  considered  at  high  surgical  risk.
Methods: We  considered  all kidney  transplant  recipients  as high-risk  patients,  which  are  candidates
for  TAVI.  In 2010  and  2011,  eight  kidney  transplant  recipients  with  severe  aortic  stenosis  underwent
TAVI  (6  transfemoral;  2 transapical;  group  I). The  outcome  of  these  patients  was  compared  retro-
spectively  to  18 kidney  transplant  recipients  with  aortic  stenosis,  who  underwent  conventional  AVR
(group  II).
Results: Both  groups  had  similar  baseline  characteristics,  including  estimated  perioperative  risk
(EuroSCORE  group  I vs.  group  II: 9.5 ± 5.9 vs. 10.4  ±  10.5;  p =  0.829).
All  TAVI  procedures  were  performed  successfully  with  excellent  functional  results.  In the  TAVI  group
(group  I),  all  patients  were  alive  at the 12-month  follow-up  with  one  cardiovascular  event (stroke).  In
contrast,  the  surgical  group  experienced  a 30-day-mortality  of 11.1%  (n  =  2)  and  a 1-year-mortality  of
16.7%  (n = 3).
Conclusions:  Based  on  our  center’s  experience,  TAVI  appears  to be an  effective  and  safe  alternative  to
conventional  surgery  for  AVR  in  patients  with  prior  renal  transplantation.  Renal  transplantation  is  not
currently  identiﬁed  as a risk  factor  in  our  traditional  scoring  system,  and  may  need  to  be  considered
independently  when  weighing  alternatives  for AVR.
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Cardiovascular disease and infectious complications remain the
eading causes of death among kidney transplant recipients [1].
atients with chronic renal failure more often develop prema-
ure calciﬁcation of the mitral and aortic valve compared to the
eneral population [2–5]. Patients with severe symptomatic aor-
ic stenosis have a poor prognosis with medical treatment alone.
owever, patients with chronic renal failure and kidney transplant
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recipients experience an increased risk of adverse outcomes after
open heart surgery. Data from the US Renal Data System database
indicate that the intrahospital mortality of kidney transplant recip-
ients undergoing valvular heart surgery is 14% [1]. Therefore, these
patients have to be considered as high-risk patients. The num-
ber of kidney transplant recipients that may require aortic valve
heart surgery will increase as their longevity improves and as
the average age of kidney transplant recipients rises. In addi-
tion, kidney transplant recipients with severe aortic valve stenosis
are often found unsuitable for open heart surgical valve replace-
ment due to impaired kidney function, potential side effects of
immunosuppressive therapy, and related comorbidities. Further-
more, the increased susceptibility of kidney allograft failure using


















































Of note, the conventional surgical group was  at higher risk levels
expressed by a higher STS-Score mainly driven by the necessity
of perioperative revascularization with CABG in 11 patients (61%;
Table 2).
Table 1








Age 70 ± 7 67 ± 8 0.417
Male gender (%) 5 (63%) 14 (78%) 0.635
LVEF 63.1 ± 7.0 58.2 ± 9.5 0.209
STS-Score 9.2 ± 8.2 18.8 ± 6.8 0.004
EuroSCORE 9.5 ± 5.9 8.8 ± 8.1 0.822
EuroSCORE II 5.9 ± 4.1 5.9 ± 6.1 0.909
Creatinine (mg/dl) 2.0 ± 1.3 2.1 ± 1.3 0.839
AVA (cm2) 0.9 ± 0.1 0.7 ± 0.1 0.030
Transaortic mean gradient 48.5 ± 12.9 51.7 ± 13.8 0.611
Transaortic max  gradient 72.4 ± 22.1 80.3 ± 21.1 0.432
Diabetes 7 (88%) 5 (28%) 0.009
CAD  6 (75%) 13 (72%) >0.999
COPD 3 (38%) 2 (11%) 0.281
PVD 1 (13%) 7 (39%) 0.360
Carotis stenosis 4 (50%) 3 (17%) 0.149
Previous cardiac surgery 1 (13%) 1 (6%) 0.52924 H. Fox et al. / Journal of C
xtracorporeal circulation (ECC) may  alter the prognosis of kid-
ey transplant patients undergoing cardiac surgery [6]. Recently,
ranscatheter aortic valve implantation (TAVI) has demonstrated
mproving survival, quality of life, and functional status in non-
perable patients and has been shown to be a viable option in
igh-risk patients [7]. The choice for either percutaneous or surgi-
al procedure is usually evaluated by estimating the perioperative
isk using risk scores based on logistic regression analysis, such as
he logistic EuroSCORE [8–10]. A logistic EuroSCORE of more than
0 is considered to be at very high surgical risk [11,12] but other
elevant risks, including chronic immunosuppressive therapy with
ll sequelae and associated comorbidities are not assessed in this
coring system. It is unknown if TAVI could be a viable alternative
or kidney transplant recipients needing aortic valve replacement
AVR).
ethods
haracteristics of the study – study population
The purpose of this retrospective study was to investigate the
utcome of kidney transplant recipients undergoing TAVI follow-
ng a speciﬁc protocol and compare this group to a historical
roup of patients undergoing conventional AVR. We  reviewed all
atients who had previously received kidney transplantation and
nderwent TAVI from 2010 to 2011 at our institution. We  identi-
ed eight kidney transplant recipients with severe aortic stenosis
ho underwent TAVI (6 transfemoral; 2 transapical; group I).
he outcome of these patients was compared retrospectively to
 population of 18 kidney transplant recipients with aortic steno-
is who underwent conventional AVR from 1998 to 2010 (group
I).
TAVI procedures were all performed at the University Hospital
n Frankfurt. Conventional heart surgery (group II) was  per-
ormed at our center (N = 15) and different external centers (N = 3).
ACE (Major Adverse Cardiac Events) were evaluated for both
roups.
rocedures
Data from medical history and reports of all diagnostic tests
ncluding blood tests were acquired. We  systemically reviewed all
edical records as well as interventional and surgical protocols.
atients were divided into 2 groups according to the chosen method
f AVR:
. Transcatheter aortic valve implantation (TAVI); group I
. Open-heart surgical AVR; group II
a. Exclusive open-heart surgical AVR
b. Open-heart surgical AVR + CABG (coronary artery bypass
grafting)
For all study patients we calculated the logistic
uroSCORE and the EuroSCORE II using the calculator on
ttp://www.EuroSCORE.org/calc.html. Furthermore we  calcu-
ated the Society of Thoracic Surgeons’ (STS) risk model using its
alculator on http://209.220.160.181/STSWebRiskCalc261.
ollow-up
All patients underwent follow-up in our Academic Medical
enter in cooperation with an associated kidney transplant
utpatient clinic (“KfH Kuratorium für Dialyse und Nierentrans-
lantation e.V.”). Clinical long-term follow-up data regarding
urvival were available in 26 (100%) patients with a meanlogy 61 (2013) 423–427
follow-up of 3.4 years for all patients after valve implantation.
We  deﬁned as the primary endpoint a combined endpoint of
perioperative death, stroke, acute renal failure, postoperative
sepsis, need for re-thoracotomy in the perioperative period (until
day 30), and prolonged initial hospital stay longer than 30 days.
Secondary endpoint was  all-cause mortality in the long-term
follow-up.
Statistics
Data are expressed as percentages for discrete variables
and as mean ± SD for continuous variables. Continuous vari-
ables were compared by ANOVA. Categorical comparisons
were done by Chi-square analysis. Statistical signiﬁcance
was assumed at p < 0.05. All statistical analyses were per-




In the TAVI group, eight kidney transplant recipients with
severe aortic stenosis underwent TAVI [6 transfemoral (TF)
(75%); 2 transapical (TA) (25%); 7 Edwards Sapien® (Irvine,
CA, USA); 1 Medtronic CoreValve® (Minneapolis, MN,  USA)]
at the University Hospital of Frankfurt in 2010 and 2011.
Preprocedural preparation and postprocedural care was
performed following a speciﬁc protocol for patients with
chronic immunosuppression, including antiinfectious prophy-
laxis and monitoring. TF procedures were performed under
local anesthesia and TA procedures under general anesthe-
sia.
The baseline clinical, surgical, and procedural characteristics of
the study population are summarized in Table 1, separately for the
two predeﬁned groups. The TAVI group and the surgical group were
comparable with regard to age, gender, left ventricular ejection
fraction (LVEF), baseline serum-creatinine level, AVA (aortic valve
area), and transvalvular gradients.Pulmonary hypert. (>60 mmHg) 2 (25%) 0 (0%) 0.086
Previous stroke 0 (0%) 1 (6%) >0.999
ICU  stay (days) 5.9 ± 6.7 10.8 ± 14.5 0.382
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rocedural characteristics and outcome of the TAVI group
Only one patient had to be scheduled for percutaneous revas-
ularization of signiﬁcant coronary artery disease before the
rocedure. TAVI was performed in this patient after a time inter-
al of more than 14 days to avoid recurrent exposure to contrast
ye during a short period in a patient with CKD (chronic kid-
ey disease IV). The mean duration of the TAVI procedures was
38 ± 115 min, and 216 ± 196 ml  of contrast dye was necessary.
wo patients received a 23 mm aortic stent prosthesis (n = 2,
5%), ﬁve patients received a 26 mm aortic stent prosthesis (n = 5,
2.5%), and one patient received a 29 mm  aortic stent prothe-
is (n = 1, 12.5%). No severe complications such as acute renal
ailure (post-intervention s-creatinine [mg/dl] at 24 h 1.88 ± 0.77;
8 h 1.93 ± 0.84; 72 h 1.81 ± 0.78; discharge 1.87 ± 0.76), noso-
omial infection, or in-hospital mortality occurred. One patient
ad a stroke within the ﬁrst 30 days. Median intensive care
nit (ICU)-stay was 3.5 days, and median hospitalization was
8 days. All procedures were performed successfully with excel-
ent functional results and well preserved allograft function
uring a follow-up time of at least one year. In addition,
ll patients were alive at the 12-month follow-up with only
ne cardiovascular event (periprocedural stroke as mentioned
bove).
able 2
ourse of group 2 (conventional surgical group).
Age/gender Log EuroSCORE Operation Complications un
67 male 11.8 AVR Sepsis
Prolonged hospita
72  male 9.6 AVR + CABG Aortic arch dissec
Re-thoracotomy d
Death on day 14
79 male 5.5 AVR + CABG Sepsis, death on d
complications
69  male 9.9 AVR + CABG No complications
79  male 5.5 AVR No complications
78  male 10.0 AVR + CABG Unknown (extern
62  female 18.9 AVR + CABG Sepsis, prolonged
Death on day 48
75 male 14.1 AVR + CABG Unknown (extern
59  male 35.8 AVR Sepsis, prolonged
Re-thoracotomy d
58  female 5.3 AVR + CABG Re-thoracotomy
67  male 4.1 AVR + CABG Re-thoracotomy
66  male 2.4 AVR Re-thoracotomy
54  male 4.6 AVR No complications
60  male 3.1 AVR + CABG Unknown (extern
68  male 5.1 AVR Acute renal failure
62  male 3.5 AVR + CABG Sepsis, wound inf
62  female 2.5 AVR + CABG Sepsis, TIA/stroke
76  female 6.2 AVR No complications
able 3
ourse of group 1 (transcatheter group).
Age/gender Log EuroSCORE Access type Complications un
66 female 3.58 Transfemoral A. iliaca perforatio
76  female 12.0 Transapical Left ventricle rupt
and ventricle sutu
77  female 11.29 Transfemoral No complications 
67  male 10.41 Transfemoral Postprocedural co
pacemaker implan
67  male 20.27 Transapical No complications
73  male 3.99 Transfemoral Failure of closure 
Postprocedural ce
56  female 2.85 Transfemoral Postprocedural co
pacemaker implan
73  male 11.55 Transfemoral No complicationslogy 61 (2013) 423–427 425
Procedural characteristics and outcome of the conventional
surgical group
Seven patients received an isolated AVR surgery, while the other
11 patients received combined CABG and AVR surgery. In con-
trast to the TAVI group, fatal complications occurred in group II
(2 perioperative deaths, 11.1%). Individual patient characteristics,
procedure performed, and the postoperative course are summa-
rized in Table 2. This group experienced a 30-day-mortality of 11.1%
(n = 2) and a 1-year-mortality of 16.7% (n = 3). Additional events in
group II included cerebral hemorrhage, acute renal failure, sepsis,
re-thoracotomy, and prolonged hospitalization longer than 30 days
as described in Table 2.
Comparison of the outcome between the two groups
The primary endpoint occurred in 10 patients in group II as
compared to 1 patient in group I (surgical group N = 10, 56% vs.
N = 1, 13% in the TAVI group, p = 0.049, one-sided test) suggesting a
possible advantage of TAVI regarding perioperative morbidity and
mortality despite the limitations of the study design (see ‘Limita-
tion’ section). TAVI is associated with a reduced 30-day-mortality
of about 30% [hazard ratio (HR): 0.67; 95% conﬁdence interval (CI)
0.50–0.89] and a 40% reduction in the primary endpoint (HR: 0.59;
til day 30
lization
tion during surgery with need for replacement, stroke on day 1
ue to bleeding










n following vascular surgery
ure after removal of the apical sheath, following heart-lung-machine surgery
re, recovery without residuum
acute renal failure and dialysis, liver insufﬁciency dermal bleeding complications
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5% CI 0.35–0.98). All complications in the TAVI group are summa-
ized in Table 3. Furthermore signiﬁcant differences between the
wo groups were found for the mean ICU stay and hospital stay
Table 1).
redicted 30-day mortality by surgical risk scoring (logistic
uroSCORE)
Predicted 30-day-mortality in the TAVI group was 5.9%, while
n this study all patients of the TAVI group survived (30-day-
ortality: 0%). Predicted 30-day-mortality by EuroSCORE in the
urgical group was 8.1%, which closely met  the existing 30-day-
ortality in this study of the surgical group of 11.1%.
iscussion
Our study provides for the ﬁrst time data on 30-day-mortality
nd one-year-mortality after AVR in a population of kidney trans-
lant recipients. We  compare an interventional TAVI group with
n historical conventional surgical group. In addition, we  investi-
ated the applicability of the EuroSCORE, EuroSCORE II, and STS risk
odel in predicting the outcome in this speciﬁc population, known
o be at an increased surgical risk due to immunosuppression and
mpaired renal function. The mortality of the renal transplant recip-
ents undergoing open heart surgery (group II) was markedly higher
ompared to the overall mortality of valve surgery at our institution.
rom 2004 to 2010, a total of 1867 isolated AVRs were performed
t the University Hospital Frankfurt. One-year-mortality of this
opulation was 3.9% (n = 74). The 1-year mortality for octogenari-
ns (n = 320) was 9.1% (n = 29) and even lower compared to 15.8%
-year-mortality of group II in the provided population.
Our data suggest TAVI to be an effective and safe method to
reat kidney transplant recipients with high-grade aortic stenosis
nd is associated with lower morbidity and mortality compared
o conventional open-heart surgery. Despite comparable baseline
arameters, the major difference in baseline parameters in group
 and II was a higher rate of combined procedures performed in
roup II. It has to be noted that the surgical group consists of
nly seven patients that received an isolated AVR surgery, while
he other 11 patients received combined CABG and AVR surgery,
hich may  affect outcomes. This difference results in a markedly
igher STS-score in the surgical group II. In the TAVI group I only
ne patient had to be scheduled for percutaneous revasculariza-
ion of signiﬁcant coronary artery disease before the procedure. In
ddition we did not distinguish if the leading disease causing heart
urgery was aortic stenosis or coronary artery disease in the surgi-
al group. Aortic stenosis is a progressive disease, therefore AVR is
enerally recommended in patients with at least moderate aortic
tenosis when performing open heart surgery [13]. Data regarding
ardiac survival outcomes in renal transplant patients are limited,
ut our excellent results with TAVI are encouraging. Furthermore
o acute kidney failure was identiﬁed in our TAVI patients. This
act may  be important because of the association of kidney failure
ith adverse outcomes following TAVI [14]. In addition, scien-
iﬁc literature on surgical high-risk populations receiving AVR is
imited. The PARTNER trial was restricted to patients with a logistic
uroSCORE above 20 [7]. Amonn et al. reported in a recent study
hat selected high-risk patients undergoing TAVI using transapical
ccess achieve similar clinical outcomes and quality of life com-
ared with patients undergoing surgical AVR [15]. Furthermore,
ncreased STS scores have been associated with less quality of life
utcomes. Our study did not assess quality of life. But our high-
isk population experienced lower mortality and morbidity in the
AVI group than those who underwent surgical AVR. TAVI appears
o be a safe and reliable alternative for this rarely investigatedlogy 61 (2013) 423–427
population of surgical high-risk patients with kidney transplants.
Furthermore, the higher perioperative risk in kidney transplant
recipients cannot be identiﬁed by calculating the EuroSCORE. The
preoperative risk scoring by logistic EuroSCORE and EuroSCORE II
predicted quite accurately the observed mortality in the surgical
group, although the average score did not exceed the established
high-risk level above 20. This was contrary to reported investi-
gations where an overestimated mortality risk assessment was
assumed [16].
In contrast, data from a German study showed that mortality
after isolated AVR in late octogenarians was  underestimated by
the EuroSCORE [17]. A similar underestimation of risk may  occur
with renal transplant patients. Thereby catheter-based aortic valve
implantation was considered to be a reasonable alternative.
The STS risk model scores exceed the EuroSCORE’s predicted
mortality by nearly 100% in group II. The STS-Score covers
additional factors such as immunosuppressive therapy, cardiac
arrhythmias, accompanying valvular heart disease and coronary
artery disease. In addition, only the STS-Score and EuroSCORE II
provide a predicted risk assessment for a combined valve replace-
ment and CABG surgery.
But anyway these data strongly suggest that indication for TAVI
in kidney transplant recipients with aortic stenosis might be gen-
erated independently from standard scoring systems. These results
may raise hope for these surgical high-risk patients in need of AVR.
Summary
TAVI is an effective and safe method to treat kidney transplant
recipients with high-grade aortic stenosis and is associated with
lower morbidity and mortality compared to conventional open-
heart surgery. Indications for TAVI in kidney transplant recipients
with aortic stenosis might be generated independently from tradi-
tional scoring systems.
Limitations
Our study is limited due to a small patient population and
a lack of randomization of surgical AVR and TAVI. The popu-
lation size is not powered regarding single endpoints. The two
groups appeared to be similar in their baseline parameters includ-
ing logistic EuroSCORE. Nevertheless, the conventional surgical
group underwent combined operation (AVR + CABG) in 61% of cases
(N = 11) and this may  have an effect on outcomes. Only one patient
in the TAVI group had revascularization before the procedure.
Therefore the conclusion is rather hypothesis-generating than con-
clusive. A randomized trial with a higher number of patients would
be warranted.
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